Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-11-12

FDA Approved: ALFUZOSIN HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

FDA approves a supplemental application for Alfuzosin hydrochloride extended-release from Cipla USA Inc., authorizing changes to the approved product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ALFUZOSIN HYDROCHLORIDE EXTENDED RELEASE (alfuzosin hydrochloride extended-release)

Snippet

SUPPL AP for ALFUZOSIN HYDROCHLORIDE EXTENDED RELEASE (ALFUZOSIN HYDROCHLORIDE)